Targeted Oncology - Immunotherapy, Biomarkers, and Cancer ...
By Jim Kling. November 7th 2024. Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to target the BCR-ABL fusion in chronic myelogenous leukemia. FDA Grants Orphan …
Adjuvant T-DM1 Continues to Outperform Trastuzumab in ...
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Targeting STK11 Mutations in Cancer - Targeted Oncology
Jan 29, 2022 · David R. Gandara, MD. STK11 mutation recently have become a biomarker and potential target of interest, especially for patients with lung cancer. Recent trials explore drugs like bemcentinib, everolimus, talazoparib, and others for potential approaches to …
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
Jan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers ...
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
Trastuzumab Deruxtecan in DESTINY-Breast04 Meets Key End …
Feb 23, 2022 · Destiny-Breast04 is a study of about 557 patients with HER2-low, unresectable and/or metastatic breast cancer who are treated with either trastuzumab deruxtecan or chemotherapy of physician’s choice. The study follows a multicenter, randomized, open-label, active controlled trial design with a goal of determining the safety and efficacy of ...
RMC-9805 Hits Milestone in Early-Phase Clinical Trial of KRAS …
Sep 24, 2023 · The oral, covalent, mutant-selective KRAS inhibitor, RMC-9805, has been dosed for the first time in a patient with a KRAS -G12D-mutant solid tumor, marking the beginning of a phase 1/1b clinical trial (NCT06040541). 1. The study follows a multicenter, open-label, dose-escalation, and dose-expansion design.
NCCN Updates Breast Cancer Guidelines to Include Goserelin
In the January 25, 2024, update to Version 1.2024 of the NCCN invasive breast cancer guidelines, under principles for adjuvant endocrine therapy, the gonadotropin releasing hormone agonist goserelin is specified as a means for ovarian function suppression.2 It is administered subcutaneously at a dose of 3.6 mg every 4 weeks or 10.8 mg every 12 ...
MEK Inhibitors - Targeted Oncology
Apr 23, 2014 · MEK Inhibitors. The RAS-RAF-MEK-extracellular signal–regulated kinase 1 and 2 (ERK1/2) pathway is the most mutated pathway in human cancer. Thus, components of this pathway have been seen as promising targets for cancer therapy. Alex A. Adjei, MD, PhD. Professor and Chair, Department of Medicine. Senior Vice President of Clinical Research.
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.